Showing results (451-460 of 466) with videos related to

Sort By:
Pageof 47
Chemistry & Biology|March 13, 1999
Renin inhibition by substituted piperidines: a novel paradigm for the inhibition of monomeric aspartic proteinases?C Oefner, A Binggeli, V Breu, et al.
British Journal of Haematology|September 1, 2001
Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study GroupM Hallek, B Schmitt, M Wilhelm, et al.
Bioorganic & Medicinal Chemistry Letters|September 22, 2000
1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitorsJ Dumas, H Hatoum-Mokdad, R Sibley, et al.
Bioorganic & Medicinal Chemistry Letters|September 22, 2000
Discovery of a new class of p38 kinase inhibitorsJ Dumas, R Sibley, B Riedl, et al.
JAMA Surgery|August 18, 2016
The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary HyperparathyroidismScott M Wilhelm, Tracy S Wang, Daniel T Ruan, et al.
European Journal of Preventive Cardiology|August 20, 2015
Sudden cardiac arrest in sports - need for uniform registration: A Position Paper from the Sport Cardiology Section of the European Association for Cardiovascular Prevention and RehabilitationE E Solberg, M Borjesson, S Sharma, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 2001
p38 kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureasA M Redman, J S Johnson, R Dally, et al.
Cancer Research|October 7, 2004
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesisScott M Wilhelm, Christopher Carter, Liya Tang, et al.
Critical Care Explorations|May 4, 2022
A Multicenter Evaluation of the Seraph 100 Microbind Affinity Blood Filter for the Treatment of Severe COVID-19Stephen A Chitty, Sarah Mobbs, Brian S Rifkin, et al.
Leukemia|July 30, 2003
Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyureaR Hehlmann, U Berger, M Pfirrmann, et al.
Pageof 47